Warther Private Wealth LLC Boosts Holdings in Novo Nordisk A/S (NYSE:NVO)

Warther Private Wealth LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 14.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,021 shares of the company’s stock after buying an additional 1,497 shares during the quarter. Novo Nordisk A/S comprises approximately 0.3% of Warther Private Wealth LLC’s holdings, making the stock its 28th largest position. Warther Private Wealth LLC’s holdings in Novo Nordisk A/S were worth $1,034,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of NVO. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S during the third quarter valued at approximately $28,000. Capital Performance Advisors LLP bought a new stake in Novo Nordisk A/S in the third quarter worth $42,000. Carolina Wealth Advisors LLC purchased a new stake in Novo Nordisk A/S during the third quarter valued at $48,000. Dunhill Financial LLC lifted its position in Novo Nordisk A/S by 196.8% during the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock valued at $56,000 after purchasing an additional 311 shares during the last quarter. Finally, Albion Financial Group UT grew its stake in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after buying an additional 278 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on NVO shares. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Price Performance

NVO opened at $83.78 on Wednesday. The company has a quick ratio of 0.75, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The business has a fifty day moving average of $90.96 and a 200 day moving average of $110.91. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The stock has a market cap of $375.95 billion, a P/E ratio of 25.46, a PEG ratio of 0.96 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is currently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.